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ABSTRACT Enterotoxigenic Escherichia coli (ETEC) causes diarrheal illness in infants
in the developing world and travelers to countries where the disease is endemic, in-
cluding military personnel. ETEC infection of the host involves colonization of the
small intestinal epithelium and toxin secretion, leading to watery diarrhea. There is
currently no vaccine licensed to prevent ETEC infection. CFA/I is one of the most
common colonization factor antigens (CFAs). The CFA/I adhesin subunit, CfaE, is re-
quired for ETEC adhesion to host intestinal cells. Human antibodies against CfaE
have the potential to block colonization of ETEC and serve as an immunoprophylac-
tic against ETEC-related diarrhea. Mice transgenic for human immunoglobulin genes
were immunized with CfaE to generate a panel of human monoclonal IgG1 antibod-
ies (HuMAbs). The most potent IgG1 antibodies identiﬁed in the in vitro functional
assays were selected and isotype switched to secretory IgA (sIgA) and tested in ani-
mal colonization assays via oral administration. Over 300 unique anti-CfaE IgG1
HuMAbs were identiﬁed. The lead IgG1 anti-CfaE HuMAbs completely inhibited hem-
agglutination and blocked adhesion of ETEC to Caco-2 cells. Epitope mapping stud-
ies revealed that HuMAbs recognized epitopes in the N-terminal domain of CfaE
near the putative receptor binding site. Oral administration of anti-CfaE antibodies in
either IgG or sIgA isotypes inhibited intestinal colonization in mice challenged with
ETEC. A 2- to 4-log decrease in CFU was observed in comparison to mice challenged
with irrelevant isotype controls. We identiﬁed fully human monoclonal antibodies
against the CfaE adhesion domain that can be potentially employed as an immu-
noprophylactic to prevent ETEC-related diarrhea.
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Enterotoxigenic Escherichia coli (ETEC) is one of the main causes of diarrhea in infantsin the developing world as well as the major cause of traveler’s diarrhea (1).
Transmission of ETEC occurs when contaminated food or water is ingested. ETEC
infections are characterized by diarrhea, vomiting, stomach cramps, and in some cases
mild fever. Symptoms usually occur 1 to 3 days after infection and last for a few days
(2). When adult travelers develop ETEC diarrhea, a short course of antibiotics can
decrease the duration and volume of diarrhea. However, ETEC strains are becoming
increasingly resistant to antibiotics (3–5), and there are currently no licensed vaccines
for protecting travelers against ETEC diarrhea.
ETEC mediates small intestine adherence through ﬁlamentous bacterial surface
structures known as colonization factors (CF). Once bound to the small intestine, the
bacteria produce heat-labile toxins (LT) and/or heat-stable toxins (ST) that, through a
cascade process, cause a net ﬂow of water from the cell into the intestinal lumen,
resulting in watery diarrhea (6, 7). ETEC vaccine development efforts have focused on
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the induction of host immunity against CFs or toxins by using cellular or subunit-based
approaches. LT has been considered a possible target based on its strong immunoge-
nicity, while ST was not initially considered due to poor immunogenicity and potent
toxicity. Progress has been made recently in the identiﬁcation of effective LT-ST toxoids
(8, 9). However, anti-ST and anti-LT antibody responses may not be sufﬁcient for
effective protection against ETEC diarrhea (8). Instead, the toxin itself may be useful as
an adjuvant to improve immunogenicity and efﬁcacy when combined with the anti-
colonization response (10).
Development of an effective immunoprophylactic against ETEC bacterial attach-
ment and colonization has long been considered an effective approach to prevent ETEC
diarrhea (11, 12). The attachment and colonization steps are critical for bacteria to
effectively produce toxin and represent a potential strategic target for preventing ETEC
infection. The ﬁrst human-speciﬁc ETEC ﬁmbria to be described was colonization factor
antigen I (CFA/I) (13). CFA/I is one of the most prevalent colonization factor antigens
expressed by pathogenic ETEC isolates (14, 15). CFA/I is composed of a minor adhesin
subunit (CfaE) at the tip of the ﬁmbria that stabilizes the structure and a long
homopolymeric subunit (CfaB) that makes up the stalk of the structure.
Recent studies have demonstrated that the adhesin subunit itself can provide
sufﬁcient immunity to prevent ETEC adhesion and subsequent infection (16, 17). In
animal models, maternal vaccination with CfaE resulted in passive protection of neo-
natal mice from lethal challenge with ETEC strain H10407. In human clinical trials, a
hyperimmune bovine IgG (bIgG) was generated by immunization of a cow with a
recombinant form of CfaE and evaluated as a prophylactic treatment in healthy
volunteers challenged with ETEC. Oral administration of bIgG antibodies raised against
the CFA/I minor pilin subunit, CfaE, led to the protection of over 60% of the test group,
suggesting that adhesin-based protective antibodies could be used as immunoprophy-
laxis against ETEC infection (16).
Here we describe the identiﬁcation of a panel of anti-CfaE human monoclonal
antibodies (HuMAbs) that are active against wild-type (or fully virulent) ETEC with high
potency in functional assays. Oral administration of the lead HuMAbs in either the IgG
form or the secretory IgA (sIgA) form, the immunoglobulin predominantly secreted at
mucosal surfaces, led to 1- to 2-log10 decreases in CFU in an animal model with ETEC
challenge. These anti-CfaE HuMAbs have the potential to be explored as oral immu-
noprophylaxis against ETEC infection.
RESULTS
Generation of anti-CfaE HuMAbs. The N-terminal portion of the adhesin CfaE acts
as the receptor binding domain of CFA/I adhesion to host cells (18, 19). To generate a
panel of HuMAbs that can provide antiadhesive immunity, eight mice transgenic for
human immunoglobulin heavy and light chain genes (Bristol-Myers Squibb; HuMAb
mice) were immunized with the N-terminal adhesin domain of CfaE fused to maltose
binding protein (MBP–CfaE-N). Serum response to MBP–CfaE-N was measured by
enzyme-linked immunosorbent assay (ELISA). Spleens from mice with a positive ELISA
response were harvested and fused to melanoma cells to generate hybridomas. A total
of 1,895 hybridomas were found reactive to MBP–CfaE-N but not the MBP tag itself.
Reverse transcription (RT)-PCR was performed on 900 hybridomas to determine the
antibody heavy chain gene sequences. A total of 360 HuMAbs with unique sequences
were selected for further characterization.
Selection of 10 lead HuMAbs in MRHA assays. All 360 unique HuMAbs were
puriﬁed and tested for their ability to inhibit mannose-resistant hemagglutination (MRHA)
of human group A erythrocytes. MRHA has long been considered a surrogate method for
the assessment of ETEC adhesion to the intestinal mucosa (20). The results of the MRHA
assays were reported as the maximal inhibitory concentration (IC100). Thirty-six of all 360
HuMAbs showed IC100 activity in the nanomolar concentration range. Ten HuMAbs were
selected as lead candidates, with IC100 values between 0.13 g/ml and 0.24 g/ml. The
heavy chain and light chain gene regions of the lead HuMAbs were ampliﬁed from
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hybridoma cells and cloned into an immunoglobulin G1 expression vector for antibody
expression and puriﬁcation as previously described. Heavy and light chain variable gene
families of the lead HuMAbs are reported in Table 1.
Anti-CfaE HuMAbs bind to recombinant CfaE and live ETEC strain. ELISA results
showed that the concentration-dependent binding activities to CfaE by the lead
HuMAbs were indistinguishable (Fig. 1A). To further differentiate the CfaE-binding
activities of HuMAbs, antibody afﬁnity was analyzed by surface plasmon resonance
using recombinant MBP–CfaE-N. All 10 HuMAbs showed high afﬁnities to MBP–CfaE-N
with dissociation constant (Kd) values in the low nanomolar range (0.6 nM to 1.2 nM)
(Fig. 1B). HuMAb 837-6 showed the highest afﬁnity of the 10, with a Kd value of 2.3 
1010. HuMAbs 68-51, 68-97, 67-102, 68-48, and 837-6 were found to have higher
afﬁnities than HuMAbs 68-61, 68-90, 840-53, and 68-75.
To assess HuMAb recognition of CfaE expressed by live bacteria, strain H10407 was
grown under an iron starvation condition to induce CfaE protein expression (21). The
bacteria were then incubated with each of the lead 10 HuMAbs, followed by
ﬂuorescence-conjugated secondary antibody and ﬂuorescence-activated cell sorting
(FACS) analysis. All HuMAbs showed strong binding activity to strain H10407. The
binding activities were comparable among all 10 antibodies (Fig. 1C).
Anti-CfaE HuMAbs prevent ETEC adherence to intestinal cells at low concen-
trations. To determine whether the lead HuMAbs were capable of inhibiting bacterial
adhesion, a cell adhesion assay with Caco-2 cells (a human intestinal epithelial cell line)
was performed. An example of a concentration-dependent inhibition curve is shown in
Fig. 2B. The minimal inhibitory concentration needed to prevent 50% (IC50) of bacterial
adhesion was reported as representing antibody potency. All 10 HuMAbs showed
TABLE 1 Anti-CfaE HuMAb heavy and light chain variable gene families
Clone
Gene family for:
Heavy chain Light chain
VH D JH VL JK
68-51 4-34 2-08 3 1-12 2
68-61 1-69 2-21 3 1-16 2
68-97 4-34 7-27 3 1-12 2
68-90 4-34 7-27 3 1-12 2
68-75 4-34 2-02 6 1-13 1
67-102 4-34 2-15 3 1-12 4
840-53 30-30 7-27 4b 1-06 1
68-48 4-34 7-27 6 1-13 1
837-6 3-23 6-06 2 1-27 5
68-06 1-69 4-17 3 1-16 2
FIG 1 Binding of anti-CfaE MAbs. (A) ELISA. IgG bound to immobilized recombinant CfaE-N was detected with an anti-human IgG Fc chain-speciﬁc alkaline
phosphatase-conjugated antibody. Error bars represent the range in OD values observed in two independent experiments. The binding curves of the 10
anti-CfaE MAbs are superimposed. (B) Surface plasmon resonance was used to measure the equilibrium dissociation constant (Kd). Error bars represent the
standard deviation of results of two independent experiments. Results for all of the anti-CfaE antibodies were signiﬁcantly different from those for the 68-6
HuMAb (P  0.0001). Symbols represent signiﬁcant differences (P  0.01) between the anti-CfaE HuMAbs using one-way ANOVA. (C) Direct binding to live
bacterial cells measured by ﬂow cytometry. The gray ﬁlled area represents bacteria incubated with an irrelevant antibody.
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strong potency to block bacterial adhesion at IC50 concentrations between 0.3 and 1.3
g/ml. HuMAbs 68-51, 68-61, and 68-97 were found to have the lowest IC50s (Fig. 2C).
Interestingly, HuMAbs showing comparable activities in MRHA assays (Fig. 2A) were
more variable in their activities in Caco-2 cell adhesion assays.
Epitope mapping of lead anti-CfaE HuMAbs. To deﬁne the antibody-binding
epitope, putative antibody-antigen interaction models were established based on a
previously resolved CfaE structure (PDB ID 2HB0) and the lead HuMAb sequences using
an antibody modeling program, BioLuminate (Schrodinger). This software suite devel-
ops models of antibody structures from their sequences, followed by computational
docking to identify high-conﬁdence antibody-antigen complex models. Based on these
models, the software identiﬁed potential residues critical for the binding interaction.
The effect of these residues on the binding activity of the HuMAbs was analyzed by
experimental alanine scanning, followed by ELISA. ELISA results indicated that mutating
ﬁve of the predicted residues to alanine affected HuMAb binding (Fig. 3). The R67A
mutation eliminated the binding activity of HuMAbs 68-51 and 68-97 (Fig. 3B), while the
Y183A mutation affected the binding activity of HuMAbs 68-51, 68-97, 68-90, 67-102,
and 840-53 (Fig. 3E). The R145A mutation abolished the binding activity of HuMAb
837-5 (Fig. 3D). The T91A mutation eliminated the binding activity of HuMAb 840-53
and reduced the binding activities of HuMAbs 68-51, 68-61, 840-53, and 68-48 (Fig. 3C).
The N127A mutation eliminated the binding activity of HuMAb 68-61 and reduced the
binding of HuMAbs 68-48 and 68-6 (Fig. 3F). A summary of the residues discovered to
affect binding are shown in Fig. 3G. All mutations were found on the surface-exposed
loops of the N-terminal domain of the CfaE (Fig. 3H). No residues involved in the
binding of MAb 68-75 to CfaE were identiﬁed.
Isotype switch of anti-CfaE HuMAbs to sIgA. Seven IgG1 HuMAbs (68-51, 68-61,
68-97, 68-90, 67-102, 68-48, and 840-53) found to have the lowest IC50s in Caco-2 cell
adhesion assays were selected as the leads for further characterization in immunoglob-
ulin class switching. Antibody variable regions were cloned into an expression vector
with an IgA constant region to generate monomeric IgA. Monomeric IgA antibodies
were also coexpressed with J chain with or without the secretory component to
produce dimeric IgA (dIgA) and secretory IgA (sIgA), respectively. Antibodies with
various isotypes were tested for their functionality in Caco-2 cell adhesion assays (Fig.
4). In general, all the antibodies retained or increased in vitro functional activity when
converted into dIgA or sIgA. Speciﬁcally, the in vitro functional activity of 68-61 was not
altered signiﬁcantly when converted to either the dimeric or secretory IgA molecule. In
contrast, Ig class switching to either dimeric or secretory IgA forms caused signiﬁcant
FIG 2 In vitro functional activity of anti-CfaE HuMAbs. (A) Hemagglutination assay. The ability of the MAbs to prevent hemagglutination is reported as the minimal
inhibitory concentration (IC100). Error bars represent the standard deviation of results observed in three independent experiments using different blood donors. (B)
Caco-2 adhesion assay. Example of inhibition curve obtained with HuMAb 68-51 and an irrelevant control. (C) The minimal effective IgG dose to prevent 50% (IC50)
of bacterial adhesion to intestinal Caco-2 cells was used to determine antibody potency ranking. Error bars represent the standard deviation of results of three or four
independent experiments. Results for all the anti-CfaE HuMAbs were signiﬁcantly different from those for the irrelevant MAb (P 0.0001). Symbols represent signiﬁcant
differences (P  0.01) within the anti-CfaE HuMAbs based on one-way ANOVA.
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improvement of functional activity for HuMAbs 68-97, 840-53, and 68-48. Interestingly,
HuMAb 68-90 saw a signiﬁcant improvement only with an Ig class switch to dimeric or
secretory IgA1. Additionally, conversion from an IgG1 to a dimeric IgA1 or IgA2 did not
affect functional activity of HuMAb 67-102, but switching from dimeric to secretory IgA1 or
IgA2 did signiﬁcantly increase the in vitro activity of 67-102. Due to low expression yields,
we were not able to generate sufﬁcient 68-51 sIgA1 or sIgA2 for in vitro testing.
Anti-CfaE HuMAbs prevent ETEC colonization in the small intestine of a mouse
model. HuMAbs 68-61, 68-97, and 840-53 were found to have the lowest IC50s as IgG1,
sIgA1, and sIgA2 and were selected as the leads for further characterization in animal
studies (Fig. 5). Groups of ﬁve DBA/2 mice were given a mixture of bacteria and
anti-CfaE HuMAbs (10 mg/kg of body weight) by oral gavage. At 24 h after challenge,
the mice were euthanized and the CFU in the small intestine were counted as described
in Materials and Methods. The efﬁcacy of the anti-CfaE HuMAbs was assessed by
determining whether the HuMAbs could prevent adhesion of bacteria to the small
intestine, in comparison to an irrelevant isotype control. In the 68-61 group, treatment
with IgG1 decreased the number of CFU by100-fold in comparison to the irrelevant
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FIG 3 Epitope mapping studies. Binding of anti-CfaE MAbs to mutants of recombinant CfaE as measured by ELISA. (A) Wild-type CfaE; (B) Arg67Ala mutant; (C)
Thr91Ala mutant; (D) Arg145Ala mutant; (E) Tyr183Ala mutant; (F) Asn127Ala mutant. (G) Summary of the amino acid residues discovered to affect binding of
anti-CfaE MAbs. (H) Crystal structure of N-terminal CfaE molecule with the ﬁve residues involved in the anti-CfaE MAb binding shown as green spheres.
Highlighted in red are the three arginines forming the putative receptor binding domain.
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antibody control. A similar result was observed for 68-61 treated with sIgA2 in com-
parison to the irrelevant control. The group of mice treated with 68-61 sIgA1 showed
slightly higher CFU than the 68-61 IgG1 and sIgA2 groups. However, the differences
were not signiﬁcant. The reductions in CFU observed in the 68-97 group in comparison
to the irrelevant control were similar across the different subclasses. In the 840-53
group, mice treated with IgG1 showed fewer bacteria than those treated with sIgA2,
FIG 4 Ig class switching of anti-CfaE MAbs, tested using the Caco-2 adhesion assay. The minimal effective
IgG dose to prevent 50% (IC50) of bacterial adhesion to intestinal Caco-2 cells was used to determine
antibody potency ranking. Error bars represent the standard deviation of results of three or four
independent experiments. *, P  0.01; **, P  0.001; ***, P  0.0001.
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while those treated with sIgA1 also showed a decrease in the number of bacteria
relative to those treated with sIgA2, though these differences were not signiﬁcant.
DISCUSSION
Recent studies from our laboratory and others demonstrated the feasibility of using
HuMAbs for preexposure prophylaxis against infectious diseases (22). A similar strategy
could be used to prevent diarrhea disease caused by enteric pathogens such as ETEC.
ETEC ﬁmbrial adhesin subunits mediate adherence of the bacteria to the small intestine
as the ﬁrst step of a cascade of events leading to diarrhea. Studies in animal models and
in human vaccine clinical trials have demonstrated that immunity against adhesion is
sufﬁcient to elicit effective protection against ETEC infection (16, 17). In the present
study, we produced and characterized HuMAbs that recognize the N-terminal portion
of CfaE (CfaE-N), the adhesin subunit involved in bacterial adhesion to host cells.
Among the 300 isolated HuMAbs, 10 lead candidates were selected based on their
ability to block mannose-resistant hemagglutination (MRHA) and to inhibit adhesion of
ETEC to Caco-2 cells. When administered orally to mice by premixing with ETEC, the
selected lead HuMAbs signiﬁcantly decrease colony formation in the small intestine.
Structural analyses have revealed a positively charged binding pocket in the
N-terminal domain of CfaE that is responsible for ETEC interaction with the negatively
charged sialic acid of the host epithelial cells (shown as a red surface in Fig. 3H). The
binding pocket is formed by three arginine residues, Arg67, Arg181, and Arg182, and
a cluster of surrounding residues, which are all highly conserved among the class 5
ﬁmbrial adhesins. Mutations of the arginine residues result in a complete loss of
binding activity of ETEC to host cells (18). Putative antibody-antigen interaction models
were established utilizing the sequences of CfaE (PDB ID 2HB0) and the anti-CfaE
HuMAbs with the aid of an antibody modeling program (BioLuminate; Schrödinger). A
set of residues predicted to be important for the binding interaction based on the
top-ranked model were selected for experimental alanine scanning and were con-
ﬁrmed to be energetically critical using ELISA. HuMAbs 68-51 and 68-97, the antibodies
with the highest in vitro functional activity, were found to bind directly to Arg67 (part
of the putative receptor binding domain). Four more residues, Arg145, Thr91, Tyr183,
and Asn127, located in the proximity of the receptor binding domain, were recognized
by the other nine lead anti-CfaE HuMAbs (Fig. 3). Together, our data suggest that the
protective HuMAbs are likely to be elicited by epitopes within or near the positively
charged binding pocket. HuMAbs binding to ETEC, either directly to the putative
receptor binding domain or its proximity region, may result in the blockage of ETEC and
host cell interactions. Unfortunately, we did not identify any residues involved in the
binding of HuMAb 68-75 to CfaE, for which a substitution different from alanine may be
required in order to elucidate the location of the epitope recognized by this MAb.
FIG 5 In vivo studies. DBA/2 mice were challenged intragastrically with 107 CFU preincubated with 10 mg/kg of
HuMAbs. Animals were euthanized 24 h after challenge, and bacterial colonies in the small intestine were counted.
Five animals were tested for each condition. Results for all the anti-CfaE HuMAbs were signiﬁcantly different from
those for the irrelevant MAb (P  0.001).
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The development of novel immunoprophylaxis to prevent disease depends on the
availability of animal models that faithfully recapitulate the disease in humans. This is
particularly the case for the development of immunoprophylaxis against ETEC, since
the colonization factors are highly species speciﬁc. In a recent study, a neonatal mouse
model using DBA/2 mice was reported to be effective in investigating an adhesin-based
vaccine. A lethal dose was determined, and the pups were rescued by maternal
vaccination or by oral administration of hyperimmune anti-CFA/I and anti-CfaE bovine
colostral IgG (16). To evaluate the potency of lead HuMAbs, we have tried to established
the same model described by Luiz et al. (16). However, maternal aggression and high
rates of pup cannibalism limited our capability to successfully conduct the assay.
Alternatively, we established an adult colonization mouse model using DBA/2 mice.
Six-week-old mice were challenged with a nonlethal dose of ETEC that would lead to
a consistent level of bacterial burden in the small intestine, as described in other studies
(23, 24). The ability of HuMAb to inhibit the adherence of ETEC was measured as a
reduction in colony count in comparison to an irrelevant isotype control.
IgG and sIgA are both present in the small intestine as effector molecules of the
mucosal immune system. sIgA is considered to be one of the most important effector
molecules because it constitutes the primary immune defense against pathogens at the
mucosal surface (25). In secretory IgA, two IgA monomers are covalently linked by a
joining chain (J chain) and stabilized by a polypeptide called the secretory component
that makes the molecule more resistant to digestion in the small intestine than IgG (26).
Early studies also have suggested that the secretory component may have its own
antimicrobial activity to block epithelial adhesion of enterotoxigenic E. coli (27). To
assess the functional differences between IgG and sIgA, three lead HuMAbs, 68-61,
840-53, and 68-97, were selected and class switched to IgA1 and IgA2 in both the
dimeric and secretory forms. The antibody activities in vivo were generally well pre-
served after the class switch. Preincubation of bacteria with either the sIgA or IgG form
led to a signiﬁcant reduction in CFU in the small intestine in comparison to the
irrelevant controls (P  0.001). 68-61 and 840-53 IgG1 showed greater activity than
their sIgA1 and sIgA2 forms, respectively, but the differences were not signiﬁcant. No
signiﬁcant differences were observed in the 68-97 group. Overall, a class switch to sIgA
did not show beneﬁts over the IgG form, possibly due to the limitation of our methods
to assess antibody efﬁcacy. In particular, full-length immunoglobulin instead of a Fab
fragment was used in our studies. We could not rule out the possibility of nonspeciﬁc
effects of the Fc portion of the anti-CfaE antibodies that may cause aggregation of the
bacteria prior to addition to the cells. In both cell adherence assays and mouse
intestinal colonization assays, the bacteria preincubated with the IgG or IgA CfaE-
speciﬁc antibodies might not have been in exactly the same state of aggregation when
they were applied directly to the Caco2 cell monolayers or used to challenge the mice.
To resolve the effect of potential aggregation caused by the Fc portion, future work
could be conducted by testing the efﬁcacy of the Fab portion of the immunoglobulin
(13).
In conclusion, we identiﬁed a panel of HuMAbs that potently inhibit ETEC binding
to intestinal epithelial cells in vitro and in vivo. Additional preclinical studies are planned
to demonstrate the safety and efﬁcacy in an Aotus monkey model with ETEC challenge
(28, 29). To date, over 25 human-speciﬁc ETEC colonization factor antigen (CFA) types
have been described, and most CFAs are ﬁmbrial proteins (30). Eight common ﬁmbriae
(CFA/I, CS4, CS14, CS1, CS17, CS19, PCF071, and CS2) belonging to class 5 are expressed
by pathogenic strains that cause the majority of moderate to severe ETEC diarrheal
cases (13, 14, 31). Anti-CfaE monoclonal antibodies have been previously shown to
cross-react and cross-protect with heterologous CFAs of the class 5 ﬁmbriae (32). For
this reason, further investigation is needed to explore the cross-protectivity of the
anti-CfaE HuMAb against heterologus CFA ETEC strains. In the absence of a vaccine for
ETEC, our study provides the ﬁrst proof of concept that oral administration of protective
antibody could potentially be an effective strategy for prophylaxis against ETEC.
Giuntini et al. Infection and Immunity
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MATERIALS AND METHODS
ETEC test strains. H10407 expressing CFA/I ﬁmbriae was purchased from ATCC (ATCC 35401). ETEC
strain H10407 was cultured on 2% agar containing 1% Casamino Acids (Sigma) and 0.15% yeast extract
(Fisher Bioreagents) plus 0.005% MgSO4 (Sigma) and 0.0005% MnCl2 (Sigma) (CFA agar plates) overnight
at 37°C. A total of 1  108 CFU/ml were resuspended in 20% glycerol (Sigma) in phosphate-buffered
saline (PBS) solution and kept frozen at 80°C until needed.
Antigen cloning, expression, and puriﬁcation. The nucleic acid sequences of N-terminal adhesin
domains of CfaE (GenBank M55661) was cloned into a pMAL-C5X vector (Addgene) in-frame with an MBP
tag to express as periplasmic proteins with improved solubility (MBP–CfaE-N).
The donor strand complement was included to ensure the overall protein expression and stability, as
reported previously (33). All cloned constructs were transformed into SHufﬂeT7 Competent Escherichia coli
(NEB), and expression was induced with 1 mM IPTG (isopropyl--D-thiogalactopyranoside). Bacteria were
lysed, and proteins were puriﬁed with amylose resin (NEB) and eluted with 20 and 50 mM maltose (Sigma).
Mouse immunization, hybridoma generation, and antibody cloning. Transgenic mice containing
human immunoglobulin genes and inactivated mouse heavy chain and  light chain genes (Bristol-Myers
Squibb) were immunized with 50 g of MBP–CfaE-N weekly with the Sigma adjuvant system (Sigma) for
6 to 10 weeks. The anti-CfaE titer in mouse serum was measured by enzyme-linked immunosorbent assay
(ELISA). Hybridomas were generated following a standard polyethylene glycol (PEG) fusion protocol (22).
Hybridoma supernatants were screened for reactivity to MBP–CfaE-N, and positive cell clones were
selected for antibody sequencing. The heavy chain and light chain variable regions were ampliﬁed from
hybridoma cells and cloned into two pcDNA 3.1 (Thermo Fisher) vectors containing  light chain constant
region and IgG1 heavy chain constant region, respectively, as previously described (22).
IgA class switching. Primers were designed to amplify the variable heavy chain of each IgG
antibody, and products were digested and ligated into a pcDNA 3.1 vector containing heavy constant
IgA1 and IgA2 chains. Each vector was transformed in NEB5- competent cells, and sequences were
veriﬁed ahead of transient transfection. In order to get dimeric IgA, the heavy and light chain vectors
were cotransfected with pcDNA-containing DNA for the connecting J chain using an ExpiCHO expression
system (Life Technology). For secretory IgA expression, a pcDNA-containing secretory component was
added to the transfection reaction in a 1:1 ratio. Supernatant was run through a column of CaptoL resin
to capture the light chains of antibodies (GE Life Sciences). Antibodies were dialyzed against phosphate-
buffered saline before being moved into size exclusion chromatography to separate out the desired
dimeric or secretory antibodies using a HiLoad 26/600 Superdex 200-pg size exclusion column (GE
Healthcare Life Sciences). The desired fractions were pooled, concentrated, and quality tested by
SDS-PAGE and Western blotting (see Fig. S1 in the supplemental material).
ELISA. For binding activity of puriﬁed HuMAbs against CfaE, 96-well plates (Nunc) were coated overnight
at 4°C with 2 g/ml of puriﬁed MBP–CfaE-N. The plates were blocked with 1% BSA plus 0.05% Tween 20 in
PBS. Puriﬁed HuMAbs were diluted in 1 PBS plus 0.1% Tween 20 and added to the plates for 1 h. The plates
were stained with alkaline phosphatase-conjugated goat anti-human IgG Fc (Jackson ImmunoResearch
Laboratories) (1:1,000) for 1 h and developed using p-nitrophenyl phosphate (ThermoFisher Scientiﬁc).
Absorbance at an optical density at 405 nm (OD405) was measured on an Emax precision plate reader
(Molecular Devices).
SPR analysis. Surface plasmon resonance (SPR) technology was used to assess the binding prop-
erties of the HuMAbs (Biacore T200 instrument; GE Healthcare). A total of 2,700 response units (RU) of
anti-human IgG MAb (human antibody capture kit; GE Healthcare) was coupled to a CM5 sensor chip
using standard amine coupling chemistry. In multicycle kinetics experiments, 25 to100 RU of each
anti-CfaE HuMAb was captured on the anti-human IgG MAb-bound sensor chip. Various concentrations
of soluble recombinant MBP–CfaE-N antigen ranging from 1.56 nM to 50 nM were injected over the chip
surface at a ﬂow rate of 30 l/min. An association step of 60 s was followed by a dissociation step of 180
s, and the ﬁnal dissociation step was 600 s. Regeneration of the sensor chip surface was accomplished
using 3 M MgCl2. Experiments were performed at 25°C. Kinetic data were analyzed using Biacore T200
Evaluation (version 3.0) software and a 1:1 binding model. All chemicals for the Biacore experiment were
purchased from GE Healthcare.
Flow cytometry. Binding of the HuMAbs to the surface of live bacteria was measured by ﬂow cytometry
as described previously (34). H10407, which expresses the target CFA/I antigen, was used as the test strain.
Brieﬂy, bacteria were grown in CFA medium supplemented with 50 M deferoxamine overnight at 37°C with
gentle shaking (21). To measure HuMAb binding, a ﬁxed concentration of anti-CfaE HuMAb (10 g/ml) or, as
a negative control, 100 g/ml of an irrelevant MAb was incubated with 107 bacteria/ml. Bound antibody was
detected using CF488-conjugated goat anti-human IgG (Biotium).
Mannose-resistant hemagglutination assay of human group A erythrocytes. ETEC cultures were
taken from frozen cell banks and diluted in a sterile 0.15 M saline solution until an OD600 of 1 was reached
for the assay. Type A-positive human erythrocytes stored in K3EDTA were washed three times with 0.15
M saline solution and resuspended in the same solution to a ﬁnal concentration of 1.5% (vol/vol). In a
U-bottom 96-well plate (Nunc Thermo Scientiﬁc), 100 l of HuMAb was added in duplicate to the top row
and diluted 1:2 down the plate in a 0.15 M saline solution. Fifty microliters of appropriately diluted ETEC
was added to each well together with 50 l of a 0.1 M D-mannose solution (sigma). The plate was
incubated for 10 min at room temperature. After incubation, 50 l of blood solution was added to the
plate and mixed well (200 l ﬁnal volume). Plates were allowed to sit stagnant at 4°C for 2 h.
Hemagglutination was then observed without the aid of magniﬁcation. The absence of a pellet of
erythrocytes at the bottom of the well is indicative of positive hemagglutination. Blood was ordered fresh
every week (BioreclamationIVT).
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Caco-2 adhesion assay. Caco-2 cells seeded at 1 105 cells/ml were grown in 24-well tissue culture
plates containing Dulbecco’s modiﬁed Eagle’s medium (DMEM), at 37°C in 5% CO2 statically. Frozen
bacterial banks were streaked on CFA agar plates and grown overnight at 37°C. The next day, bacteria
were resuspended in PBS and diluted until an OD600 nm of 0.1 was reached. HuMAb dilutions were set up
in a deep well plate. Antibody dilutions and bacteria were combined at a 1:10 ratio and allowed to shake
at 300 rpm for 1 h at room temperature. After incubation, 0.2 ml of the mixture of antibody and bacteria
was added to each well containing Caco-2 cells. The cells were then incubated statically for 3 h at 37°C.
The cells were then washed four times with 1 ml PBS to remove nonadherent ETEC cells. Afterwards,
Caco-2 cells were dislodged with 0.2 ml of 0.25% trypsin. Cells were collected via gentle centrifugation
and resuspended in 1 ml PBS. Dilutions were plated on CFA agar plates, and colonies were counted the
next day. IC50 was deﬁned as the concentration of HuMAb needed to inhibit 50% of ETEC adhesion to
the Caco-2 cells, compared to an irrelevant isotype antibody.
Animal assays. Six- to 8-week-old DBA/2 mice were pretreated with streptomycin (5 g/liter) in the
drinking water for 24 to 48 h. Twelve hours prior to bacterial administration, the water was replaced with
regular drinking water. One hour prior to bacterial administration, mice received cimetidine (50 mg/kg)
intraperitoneally to reduce the effect of stomach acid on ETEC. A total of 107 CFU of ETEC strain H10407
diluted in PBS were incubated with 10 mg/kg of an anti-CfaE HuMAb or an irrelevant MAb (puriﬁed
human secretory IgA; MP Biomedicals) 1 h prior to challenge. Bacteria and HuMAbs were administered
in a 200-l volume by oral gavage using 20-gauge bulb-tip feeding needles. The mice were allowed to
survive for 24 h. At 12 h before euthanasia, food was withdrawn. Following isolation of the small
intestine, two segments of ileum (3 cm each), beginning within 0.5 cm of the ileocecal junction and
extending proximally 6 cm, were removed and placed in 1 ml sterile PBS (23). Tissues were mechanically
homogenized. Samples were serially diluted on MacConkey agar plates and incubated overnight at 37°C.
Bacterial CFU were counted the next day. To conﬁrm that recovered bacteria were the inoculum strain,
bacterial colonies grown on culture plates were routinely tested by PCR using speciﬁc primers (23) which
ﬂank the eltAB operon encoding the LT holotoxin of H10407.
Epitope mapping. BioLuminate software (Schrödinger) was used to identify CfaE residues involved in
antibody-antigen recognition. A total of 22 amino acids predicted by the software to be involved in the
interaction between anti-CfaE HuMAbs and the N-terminal portion of CfaE were individually mutated to
alanine using the BioXp 3200 system (SGI-DNA). The genes were cloned into pMAL-C5x vector, and the
resulting 22 constructs were transformed, expressed, and puriﬁed as described above. An ELISA was
performed to determine binding of the HuMAbs to the mutant proteins in comparison to that to the wild
type.
Statistical analysis. Statistical calculations were performed using the software Prism version 7.03
(GraphPad Software, La Jolla, CA). Comparisons between the hemagglutination or Caco-2 titers of
respective antibodies were performed using multiple comparisons, the Bonferroni test, and one-way
analysis of variance (ANOVA).
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